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osting by EAbstract Diabetic neuropathy is the most common complication and greatest source of morbidity
and mortality in diabetic patients. Thirty male and female patients with painful diabetic neuropathy
and abnormal results from nerve conduction studies participated in this study. Their ages ranged
from 45 to 60 years with a mean of 52.1 ± SD 4.7 years. Patients were randomly assigned into
two equal groups of 15, an active laser group (laser group) and a placebo laser group (control
group). The laser group received scanning helium neon (He–Ne) infrared laser with wavelength
850 nm and density of 5.7 J/cm2, applied to the lumbosacral area and the plantar surface of the foot
for 15 min each site/session three times per week for four weeks (i.e. 12 sessions). Pain intensity via
visual analogue scale, bilateral peroneal motor nerves, sural sensory nerves conduction velocity and
amplitude and foot skin microcirculation, were measured pre- and post-treatment for both groups.
Pain was signiﬁcantly decreased (p 6 0.05) and electrophysiological parameters and foot skin
microcirculation were signiﬁcantly improved (p 6 0.05) in the laser group, while no signiﬁcant
change was obtained in the control group. Low level laser therapy within the applied parameters
and technique could be an effective therapeutic modality in reducing pain and improving neurovas-
cular function in patients with diabetic polyneuropathy.
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Diabetic peripheral neuropathy (DPN) is frequently the most
common microvascular complication of both type I and II dia-
betes; it is thought to be progressive and irreversible [1].Diabetic
neuropathy is a consequence of peripheral nerve injury derived
from microangiopathy of the vasa nervorum, loss of axons and
axonal atrophy as a result of the combination of different mech-
anisms of tissue damage [2]. All nerve ﬁbres may be injured but
small myelinated and unmyelinated ﬁbres that conduct pain and
temperature are most affected [3]. Not only does the nerve die,
but the repairing mechanisms of nerve regeneration are also
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circulation is responsible for the development of diabetic gan-
grene, ulcers, and infections of skin and bone in long-standing
diabetic patients [4]. In many patients with diabetic neuropathy,
pain will develop as a symptom, affecting up to 30% of the dia-
betic population; symptoms are localised to the lower extremi-
ties, primarily the soles and toes [5]. In addition to discomfort,
all areas of patients’ lives including sleep, mood, mobility, abil-
ity to work, interpersonal relationships, overall self-worth, and
independence, are affected [3].
Current therapy for DPN is purely symptomatic, aiming to
relieve the pain through the administration of various analge-
sic drugs. These drugs are effective, but no more than 40–60%
of patients show adequate symptomatic relief. Moreover, these
drugs are frequently associated with central nervous system
side effects and do not slow the progression of the underlying
neuropathy [6]. Non-pharmacological symptomatic treatments
have also been proposed, including acupuncture [7], near-
infrared phototherapy [8], low-intensity laser therapy [9,10],
static and pulsed magnetic ﬁeld therapies [11,12], and various
electrotherapies, including transcutaneous electrical nerve
stimulation (TENS) [13], percutaneous electrical nerve stimula-
tion [14] and spinal cord electrostimulation [15]. The efﬁcacy of
most conservative treatment options for painful diabetic neu-
ropathy is still little known. Among the different options for
treatment, low-level laser therapy (LLLT) may have the poten-
tial to induce a biostimulational effect on the nervous system
[16,17]. Because the typical aetiology of peripheral neuropathic
pain starts with injury to a peripheral nerve, the great majority
of research into the treatment of neuropathic pain is focused
predominantly on the nerves themselves. Several clinical and
experimental research studies on peripheral nerve injuries used
LLLT because it promotes microcirculation in the irradiated
area, increases nerve functional activity increases the rate of
axon growth and myelinization and improves regeneration of
the injured nerve [18–21]. In addition, low-power laser has also
been employed for the treatment of other diabetic complica-
tions, such as foot ulcers [22], diabetic microangiopathy
[4,23] and wound healing [24]. Therefore the purpose of this
study is to evaluate the effect of LLLT on pain intensity, mo-
tor and sensory nerve conduction velocity (NCV), and foot
skin microcirculation, in patients with painful diabetic
neuropathy.Subjects and methods
Subjects
A total of 30 patients with painful DPN were referred from the
diabetic clinic in El Kasr EL Einy Hospital and the neurolog-
ical outpatient clinic of the Faculty of Physical Therapy, Cairo
University, with a diagnosis of peripheral neuropathy con-
ﬁrmed by an abnormal nerve conduction study. Eligible pa-
tients included (20 women and 10 men), ranging in age from
45 to 60 years with a mean of 52.1 ± SD 4.7 years. The pa-
tients had longstanding type 2 diabetes associated with painful
peripheral neuropathic symptoms forP6 months (11.9 ± 3.1)
duration involving both lower extremities and complained of
burning pain with paresthesia in both legs. Neurological exam-
ination of the patients revealed sensory abnormalities in both
lower extremities. Patients were excluded from the study if theyhad unstable glycemic control and/or medical conditions that
would confound assessment of neuropathy such as malig-
nancy, active/untreated thyroid disease, peripheral vascular
diseases (PVD), vascular insufﬁciency (claudication, skin dis-
coloration, ulceration), signiﬁcant renal or hepatic disease,
pregnancy, alcohol or illicit drug abuse, nerve damage as a re-
sult of prior reconstructive or replacement knee surgery, back
surgery, spinal stenosis, spinal compression or radiculopathy
(sciatica), nonambulatory status, an ankle brachial index (A/
B index) below 0.9, and other neurologic diseases. This study
was approved by the Ethical Committee of the Faculty of
Physical Therapy, Cairo University. The study procedures
were explained and informed consent was obtained from eligi-
ble participants. Patients were randomly assigned equally into
an active laser group (laser group) and a placebo laser group
(control group). The use of analgesic or adjuvant analgesic
medications (e.g. opiates, antidepressants, anticonvulsants, lo-
cal anesthetics) was allowed but had to be unchanged for at
least four weeks before entering the study and during the
study.Instrumentation
Assessment instrument
Visual analog scale
VAS was used to assess the intensity of perceived pain. The
VAS is a reliable and valid tool for the quantiﬁcation of per-
ceived pain [25].
Electroneurography device
The Toennis Neuroscreen Plus device was used to measure
peroneal motor conduction velocity (P MCV), amplitude and
sural sensory conduction velocity (S SCV) and amplitude.
Laser Doppler ﬂow meter
The Peri Scan System was used to measure skin microcircula-
tion of feet at three different points of plantar surface [26]. La-
ser Doppler perfusion imaging is a reliable method for
characterizing microvascular changes in the human skin [27].
Treatment instrument
The Laser Scanner device (Italy ASA Co., Bravo Style), which
emits both He–Ne and infrared laser in a mixed light, was used
in the study. He–Ne was continuous with wavelength 850 nm,
while infra red was pulsed with wavelength 905 nm. The device
had maximum power of 10 W. The output of the device was
calibrated at each frequency with a power meter (Omega Laser
Systems), and an I.R. Laser Detection Card.Procedure
Medical history, demographics, physical and neurologic exam-
ination were initially performed for all patients. Pain intensity,
peroneal and sural nerve conduction studies (NCSs), and foot
skin microcirculation, were measured in all participants on
both lower limbs upon entry into the study and after four
weeks of the treatment.
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Pain intensity
In VAS, the patient was given a 10-cm line and asked to draw
on the line the intensity of pain he was feeling. The left end of
the line represented ‘‘no pain at all,’’ and the right end of the
line represented the ‘‘worst pain you can imagine.’’ The pa-
tient’s mark on the line was measured (in centimetres) with a
ruler.Macrocirculation assessment
Macrocirculation was measured along the main leg arteries,
both tibial and peroneal, by using Nicolet Vasoguared to mea-
sure the A/B index and detected any PVD and excluded those
patients that had an A/B index below 0.9.Microcirculation assessment
On the occasion of each measurement, the patient was in an
acclimatized room with a stable temperature of 22–24 C and
allowed to rest on the back in a recumbent position with both
feet supported on a pillow for at least 20 min prior to blood
ﬂow measurements. The laser was placed to scan the entire
plantar surface of both feet till the complete image of the feet
was shown on the screen. Three points of measurement (big
toe, little toe and heel) were encircled and the mean value of
microcirculation in these areas was measured and the results
expressed as perfusion ﬂux units. All measurements were per-
formed with a skin temperature at 37 C.Electrophysiological assessment
Conventional NCSs were administered using a standard test-
ing protocol. Studies included testing of bilateral peroneal
MCV and amplitude and sural SCV and amplitude. All mea-
surements were done under standard room temperature of
25 C. The skin temperature of the leg was maintained at
37 C.
Peroneal nerve MCV was measured with standard surface
electrodes with stimulation distally about 8 cm proximal to the
active pickup electrode, just lateral to the Tibialis anterior ten-
don; proximal stimulation was applied just below the head of
the ﬁbula, with the recording electrode over the Extensor Digi-
torum Brevis and the earth electrode positioned mid-calf [28].
Sural nerve SCV was measured with the active pickup elec-
trode placed posterior and below the lateral malleolus of the
ﬁbula; the reference electrode was placed 3 cm distal to the ac-
tive electrode and the earth electrode positioned between the
cathode of the stimulator and the active pickup electrode.
Stimulation was applied slightly lateral to the midline in the
lower third of the posterior aspect of the leg with the cathode
distally about 17 cm from the active electrode [28].Fig. 1 Application of laser on lumbo-sacral area.Treatment procedure
Helium neon (He–Ne) infrared laser (850 nm,) in continuous
wave (CW) mode was used for treatment in both groups. The
instrument had 25 pre-stored programmes including a pro-
gramme for DPN. The patient lay in comfortable prone posi-
tion. The distance between the laser head and the treated area
(height) was ﬁxed accurately at 30 cm. The area of treatmentincluded the whole plantar surface of the foot and the lumbo-
sacral area. The X–Y dimensions of the lumbo-sacral area was
marked by four points, one on the L2, one on the S1 and two
points laterally to the spine by about 2 cm, see Fig. 1. These
two areas were exposed to LLLT through a sweeping computer-
ized scanning at an angle of 30 ± 15 for 15 min at each site. Be-
fore laser application, the target areas were cleaned with alcohol
(95%) to minimize any backscatter or reﬂection from oily skin.
According to the pre-stored programme for DPN, the instru-
ment automatically delivered 5.7 J/cm2 at an automaticallymea-
sured therapy time. For protection from the laser’s beam, both
the subject and the physiotherapist wore protective glasses.
The same procedures were taken for the control group with
the laser device OFF. As there is no heating effect of laser and
the patient was lying prone, the patient could not detect if the de-
vice was ON or OFF. Each patient received 12 treatment ses-
sions at a rate of three sessions per week. Both groups were
treated under the same conditions, and the patients were treated
individually to avoid inﬂuencing one another.
Statistical analyses
All data are expressed as mean ± SD. Statistical signiﬁcance
was evaluated by two tailed Student’s t test (for paired and un-
paired values). Analyses were performed using GraphPadP-
rism, Version 3.0 (GraphPad Software; San Diego, CA,
USA) on a personal computer. The signiﬁcance was set at
p 6 0.05. The sample size was calculated based on previous
studies [9,10]. A power analysis with a= 0.05 and
power = 80% chance determined that a group size of 15 was
adequate to demonstrate a 25% change in the nerve conduc-
tion study results as between the groups.
Results
This study was conducted on 30 patients with painful DPN.
Fifteen patients were treated with LLLT and another 15 were
treated with a placebo laser for four weeks. The demographic
proﬁle of the patients is shown in Table 1. At baseline, there
were no statistically signiﬁcant differences in age, duration of
diabetes, duration of neuropathy and pain intensity between
the two groups.
Table 1 Demographic characteristics of patients.
Variables Groups Mean ± SD MD t p-Value
Age (years) CG 51.2 ± 5.69 1.93 1.114 0.2a
LG 53.13 ± 3.56
Duration of diabetes mellitus (years) CG 11.66 ± 3.8 0.6 0.4861 0.6a
LG 12.26 ± 2.9
Duration of neuropathy (months) CG 11.73 ± 0.51 0.27 1.367 0.18a
LG 12 ± 0.57
Sex n (male/female) CG 5/10 – – 1a
LG 5/10
Pain level intensity CG 7.2 ± 0.77 0.13 0.61 0.61a
LG 7.33 ± 0.61
SD: Standard deviation. MD: Mean difference. CG: Control group. LG: Laser group.
a Non-signiﬁcant.
Between groups difference of peroneal N MCV and Sural N SCV
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Fig. 2 Comparison of the pre- and post-treatment values
(mean ± SD) of NCV between the groups.
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At pre-treatment measurement, no signiﬁcant difference was
found between the groups for either NCV or amplitude of
peroneal nerve, see Table 2. Sural nerve response was absent
in 73% patients of the two groups and present in 27% of all
patients but with abnormal values (reduced SCV and ampli-
tude). In post-treatment measurement, sural SCV was present
in 100% of patients in the laser group and it was still absent in
the control group.
As regards NCV, in the Laser group, the peroneal and sural
nerve conduction was increased signiﬁcantly (p= 0.001 and
0.0001, respectively); there was no signiﬁcant change in the
control group (p= 0.09 and 0.07, respectively), see Table 2.
Comparing the post-treatment results of the two groups, no
signiﬁcant difference was found for peroneal MCV (p= 0.1),
but there was a highly signiﬁcant difference for sural SCV in
favour of the Laser group (p= 0.0001), see Fig. 2.
As regards the mean amplitude of the peroneal and sural
nerve action, potential was increased signiﬁcantly in the laserTable 2 Electrophysiological values of the groups pre- and post-tre
Variables Groups Pr
Peroneal nerve MCV (M/SEC) CG 47
LG 46
MD Pre 0
Post 3.3
Peroneal nerve amplitude (MV) CG 1.6
LG 1.3
MD Pre 0
Post 0.3
Sural nerve SCV (M/SEC) CG 5 ±
LG 5.1
MD Pre 0.1
Post 31
Sural nerve amplitude (MV) CG 1.6
LG 5.6
MD Pre 4.3
Post 23
M± SD, mean ± standard deviation; MD, mean difference; CG, contro
a Non-signiﬁcant.
b Signiﬁcant.group (p= 0.002 and 0.0001, respectively), with no signiﬁcant
change in the control group, see Table 2. In post-treatment
measurement, no signiﬁcant difference was found between
the groups for peroneal nerve amplitude; there was a highlyatment.
e M± SD Post M± SD t p-Value
.1 ± 5.3 46.6 ± 5 1.807 0.09a
.3 ± 6.4 50 ± 6.7 4.097 0.001b
.8 0.372 0.7a
73 1.55 0.1a
± 0.78 1.5 ± 0.8 1.910 0.07a
± 0.7 1.7 ± 0.6 3.788 0.002b
.27 0.976 0.3a
16 1.240 0.2a
9.1 4.5 ± 8 1.258 0.2a
± 9.2 36.2 ± 12.4 10.234 0.0001b
33 0.0397 0.9a
.813 8.355 0.0001b
± 2.9 1.7 ± 3 1.835 0.08a
± 10.1 26.1 ± 12.7 7.851 0.0001b
53 1.6111 0.1a
.240 6.375 0.0001b
l group; LG, laser group.
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laser group (p= 0.0001), see Fig 3.
Microcirculation results
Regarding skin blood perfusion, no statistically signiﬁcant
difference (p> 0.05) was found between the groups at pre-
treatmentmeasurement of heel, big toe and little toe, see Table 3.
In the laser group, the microcirculation at the three points was
increased signiﬁcantly (p= 0.001) with no signiﬁcant change
in the control group, see Table 3; post-treatment measurement
comparison between groups found a highly signiﬁcant differ-
ence (p= 0.001) in favour of the laser group, see Fig. 4.
Pain level results
Both groups noted a decrease in mean pain scores after four
weeks of treatment, see Table 3, with a statistically signiﬁcant
in favour of the laser group (p= 0.0001).
Discussion
From a pathophysiological standpoint, DPN is derived not
only from injury to peripheral nerves, most commonly of
microvascular origin [2,3], but repairing mechanisms are also
defective including nerve growth factor and insulin-like growth
factor [3]. So the treatment of DPN could be directed to im-
prove microcirculation, enhance regeneration of nerve injury
and reduce pain.
This study was designed to examine the effect of scanning
He–Ne laser of wavelength 850 nm to treat patients with dia-
betic polyneuropathy. The outcome measurements are consid-
ered to be relief of pain, improvement of foot skin
microcirculation, and to be measured objectively through elec-
troneurography of peroneal and sural NCV and amplitude.
Using VAS for pain assessment has some advantages in clini-
cal trials as it is the most common and reliable type of pain
scale [25]. In addition, its range and phraseology are known
to be more reliable than those of other tests [29]. In electroneu-
rography evaluation, sural SCV and peroneal MCV together
serve as a simpliﬁed and effective diagnostic tool for diabetic
polyneuropathy [30]. Peroneal nerve MCV correlates well with
sural SCV, and sural nerve latency is often absent in patients
with reduced peroneal MCV [31].Between groups difference of Peroneal 
 and Sural nerve Amplitude
0
5
10
15
20
25
30
Pre Post Pre Post
Peroneal  N Amplitude Sural N  Amplitude
M
V
Control Group Laser Group
Fig. 3 Comparison of the pre- and post-treatment values
(mean ± SD) of peroneal and sural nerve amplitude between the
groups.The study results showed that electrophysiological parame-
ters (conduction velocity and amplitude) of peroneal motor
nerve and sural sensory nerve and foot skin microcirculation
were signiﬁcantly increased in the laser group with no signiﬁ-
cant change in the control group. Also pain intensity level
was signiﬁcantly decreased in the laser group only. When com-
paring the post-treatment results of the groups, sural SCV and
amplitude, foot skin microcirculation and pain intensity, had
signiﬁcant differences in favour of the laser group; there was
no signiﬁcant difference in either peroneal MCV or amplitude.
The improvement of electrophysiological parameters (pero-
neal MCV, amplitude & sural SCV, amplitude) in the Laser
group could be explained as follows; laser has a biostimula-
tional effect on the nervous system [16]. Earlier research ﬁnd-
ings suggest that LLL treatment appears to enhance
reinnervation of target tissues subsequent to nerve injury
[18–20]. Rochkind [17] found that laser improves function
recovery and recruitment of voluntary muscle activity through
application transcutaneously to the site of nerve injury
(15 min) and to the corresponding segments of the spinal cord
(15 min). The other studies concluded that laser irradiation
prevents motor cell degeneration, induces Schwann cell prolif-
eration, allows higher neural metabolism, and increases mye-
linization and axon regeneration [21,32]. An intriguing
hypothesis would be that the improvement in cutaneous blood
ﬂow might be mirrored by a similar effect at the endoneural le-
vel, thus suggesting that an increment in nerve blood ﬂow
might be a mechanism through which laser induces improve-
ment of peripheral nerve function. Carmeliet [33] demon-
strated that blood vessels and nerves use similar signals and
principles to differentiate, grow, and navigate towards their
targets and, therefore, could also show synergistic responses
to a common stimulus such as that induced by laser. Further-
more, the possible mechanism of the action of laser with re-
spect to tissue regeneration and improved blood circulation
were due to the following effects: (1) increased activity of some
cells, such as leukocytes and phagocytes, and increased cal-
cium in the cell cytoplasm; (2) interaction with cytochromes,
stimulating redox activity in the cellular respiratory chain
and resulting in cell activation [34,35], (3) accelerated cell divi-
sion and growth; (4) activation of protein and cytokine synthe-
sis; (5) stimulation of production of adenosine triphosphate
(ATP), which enhances the cells’ mitotic activity; and (6) relax-
ation of the vessel walls (vasodilatation) by photolysis of com-
plexes such as nitric oxide [36,37].
The better response in sural sensory conduction study than
in peroneal motor conduction study may indicate that (1) laser
started its effects more peripherally in small nerve ﬁbres that
reﬂected on sural SCV and amplitude [9]; (2) sural SCV is mea-
sured through one site of stimulation and recording while
peroneal MCV is measured through two sites of stimulation
and recording that subtract the distal latency of peroneal
nerve, which may reﬂect the peripheral laser effect [28] (this
ﬁnding corresponds with the results obtained by Khullar
et al. [32] who found actual function recovery in rats with com-
pressed sciatic nerve without signiﬁcant change in the evoked
compound action potentials of the common peroneal nerve);
(3) anatomically, the sural sensory nerve is a primary afferent
neuron that is located superﬁcially in the epidermis and dermis
and was easily inﬂuenced by transcutaneous laser through
both direct application to its branches on the plantar surface
of foot and to its origin through lumbosacral application,
Table 3 Foot skin microcirculation and pain level values of the groups pre- and post-treatment.
Variables Groups Pre M± SD Post M± SD t p-Value
Heel CG 4.14 ± 1.63 4.19 ± 1.64 1.75 0.1a
LG 4.51 ± 2.27 6.18 ± 1.95 4.2 0.001b
MD Pre 0.37 1.01 0.32a
Post 1.99 4.4 0.001b
Big toe CG 4.1 ± 1.81 4.19 ± 1.82 1.85 0.08a
LG 3.97 ± 2.04 5.74 ± 1.77 9.99 0.001b
MD Pre 0.13 1.28 0.22a
Post 1.55 9.79 0.001b
Little toe CG 4.55 ± 2.8 4.73 ± 2.71 1.32 0.2a
LG 4.5 ± 1.66 5.68 ± 1.38 7.2 0.001b
MD Pre 0.05 0.12 0.9a
Post 0.95 2.2 0.04b
Pain level CG 7.33 ± 0.61 6.93 ± 0.7 1.87 0.08a
LG 7.2 ± 0.77 5.33 ± 0.97 7.29 0.001b
MD Pre 0.13 0.48 0.63a
Post 1.6 5.23 0.001b
M± SD, mean ± standard deviation; MD, mean difference; CG, control group; LG, laser group.
a Non-signiﬁcant.
b Signiﬁcant.
Between groups difference of foot skin blood 
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Fig. 4 Comparison of the pre- and post-treatment values
(mean ± SD) of foot skin microcirculation between the groups.
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inﬂuenced it only indirectly through lumbosacral application.
Parallel to the study’s ﬁndings, statistically signiﬁcant
improvements were found in SCV, and sensory and motor
distal latencies of median nerves in carpal tunnel syndrome
treated by laser [38,39].
In addition, this ﬁnding is consistent with some results of
Peric´ and Cvetkovic [10] who concluded that LILT had an
indirect inﬂuence on the sensory axons function of the ulnar
nerve (UN) in patients with painful DPN, where LILT signif-
icantly increases the neural potential amplitude of UN. But the
study is inconsistent with the other Peric´ and Cvetkovic [10]
results where LILT had no direct signiﬁcant inﬂuence on
SCV and MCV values of the peroneal nerve and the ulnar
nerve of patients with DPN. The conﬂict between the two
studies’ results may be attributable to differences in the laserparameters and techniques used; our study used a scanning
laser with wavelength 850 nm, while Peric´ and Cvetkovic [10]
used a pointer laser with wavelength 904 nm. It has be men-
tioned that laser with wavelength 904 nm has no effect on
the electrophysiological parameters of either sensory or motor
function in normal and injured sciatic nerve [40,41]. In addi-
tion Peric´ and Cvetkovic [10] used laser with shorter duration.
Regarding to blood perfusion by laser application, the
mean skin microvascular circulation measured at three differ-
ent point of foot plantar surface was found to be increased
by 35.8% in comparison with baseline. The degree of improve-
ment achieved in the present study is comparable with that of
previously published data [4,23] and with ﬁndings from studies
dealing with the effects of other treatment modalities used to
improve skin circulation in diabetic patients. This remarkable
ﬁnding may suggest that, upon treatment with laser, the skin of
individuals with diabetes generates a response at the microvas-
cular level. The most likely explanation for triggering remote
responses is the release of cytokines and growth factors into
the circulation, which are responsible for systemic vasodilata-
tion and formation of new capillaries [42,43]. Mack et al.
[44] reported that low-intensity laser-induced release of the
angiogenic cytokine was demonstrated to be the major
component in wound ﬂuid responsible for the induction of
endothelial cell surface alkaline phosphatase, which
dephosphorylates AMP to adenosine, a product of potent
vasodilatory and anti-inﬂammatory activity.
Patients receiving LLLT had a 26.4% decrease of pain level
through four weeks of treatment. Many authors had reported
signiﬁcant pain reduction with LLLT in acute and chronic
painful conditions [45,46]. The exact mechanism whereby
LLLT relieves pain is unknown. It may be due to increased
ATP production by the mitochondria, and increased cellular
oxygen consumption, increased serotonin and endorphins,
anti-inﬂammatory effects and improved blood circulation in
some cases [47]. There is also in vivo and in vitro studies evidence
that 830 nm laser inhibits Ad andC nerve ﬁbre transmission [48],
Effect of LLLT on neurovascular function of diabetic neuropathy 27given the etiology for the pain of diabetic neuropathy through
abnormal activation of damaged nerve ﬁbres, regenerating
small-diameter nociceptive ﬁbres may be involved. The percep-
tion of this pain is dependent on neurotransmission in the dor-
sal horn of the spinal cord [49]. Laser treatment would block
the abnormal activity in the affected peripheral nerve or block
neuro-transmission in the somatotopically related dorsal horn
through application of laser on the corresponding segment of
the spine (lumbosacral application). In addition transcutane-
ous or direct stimulation of sensory peripheral nerves (foot
plantar surface application) is believed to produce analgesia
through both of these mechanisms.Conclusion
The study ﬁndings indicate that LLLT could be an effective
therapeutic modality in the treatment of painful diabetic neu-
ropathy in that it is able to modify pain, foot skin microcircu-
lation and some electrophysiological parameters of peripheral
nerve function.References
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